The first company to introduce a digital radiography system in the U.S. may soon be sold. Swissray International announced Sept. 24 the signing of a nonbinding letter of intent with a U.S.-based private equity firm to acquire all the outstanding shares
The first company to introduce a digital radiography system in the U.S. may soon be sold. Swissray International announced Sept. 24 the signing of a nonbinding letter of intent with a U.S.-based private equity firm to acquire all the outstanding shares of Swissray's capital stock. Swissray has installed its CCD-based ddR (direct digital radiography) systems in the U.S., Europe, the Middle East, and Asia. The company began shopping for a buyer in February at the behest of its major shareholder Hillcrest Avenue, which owns more than 52 million of the company's 91 million common shares. The letter provides for a limited exclusivity period in which to conduct due diligence, to agree on the form and terms of the transaction, and to enter into a definitive contract. Neither Swissray nor its major stockholders may pursue other potential buyers during this time. If the letter of intent is terminated, sale to another buyer within six months will require Swissray to pay a penalty.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.